Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Looks To Model New Central Drug Authority After U.S. FDA

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - With elections to parliament slated for next year, India's Congress Party-led government is expected to soon pass a slew of bills in the pharmaceutical sector, including that for a central drug authority

You may also be interested in...



India’s Drug Watchdog DCGI Speeds Up Regulatory Overhaul; Single Window Clearance to Precede Central Drug Authority

MUMBAI - India's drug regulatory body, the Drug Controller General of India, is set for a comprehensive overhaul of its regulatory and administrative functions

India’s Drug Watchdog DCGI Speeds Up Regulatory Overhaul; Single Window Clearance to Precede Central Drug Authority

MUMBAI - India's drug regulatory body, the Drug Controller General of India, is set for a comprehensive overhaul of its regulatory and administrative functions

Parliamentary Panel Not Yet Ready To Recommend India’s CDA Bill

NEW DELHI - A parliamentary committee examining the bills to set up a central drug authority in India is not yet set to give its recommendations, which would pave the way for the bills to be debated and passed in the parliament. The CDA bill has been approved by the country's Cabinet of Ministers and is currently with the parliamentary panel

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel